Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Boehringer Ingelheim will conduct biophysical and structural ... Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and ...

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...